echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > 2021BOC/BOA: Professor Yin Yongmei interprets China's clinical practice data of CDK4/6 inhibitor Abesiride, with a view to improving accessibility

    2021BOC/BOA: Professor Yin Yongmei interprets China's clinical practice data of CDK4/6 inhibitor Abesiride, with a view to improving accessibility

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 2~3, 2021, the Chinese Society of Clinical Oncology (CSCO) and Beijing Xisk Clinical Oncology Research Foundation jointly sponsored the "2021 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2021 China" (2021 BOC/BOA) was successfully held in Chengdu
    .

    On July 2~3, 2021, the Chinese Society of Clinical Oncology (CSCO) and Beijing Xisk Clinical Oncology Research Foundation jointly sponsored the "2021 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2021 China" (2021 BOC/BOA) was successfully held in Chengdu
    .


    Breaking the predicament, CDK4/6 inhibitors bring a cross-age leap for the treatment of HR+/HER2- advanced breast cancer.
    Chinese data and changes in practice: MONARCH plus research provides CDK4/6 inhibitors that China’s evidence-based patients need urgently and need for their careers : Abbe expect Sealy into the health insurance as soon as possible, to benefit breast cancer patients more accurate times, "fine" endless: emphasis on standardized testing, formations, security management, so that patients benefit more in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.